右美托咪定复合瑞芬太尼在无痛ERCP中的临床探讨

目的：探讨右美托咪定复合瑞芬太尼在ERCP中的有效性及安全性。方法方便选择拟行ERCP术的患者62例,将其按照麻醉方法分为A组和B组,A组给予右美托咪定复合瑞芬太尼麻醉,B组患者给予丙泊酚复合瑞芬太尼麻醉,分别记录2组患者个各时段血压、HR、呼吸频率(RR)等相关指标。结果手术开始后,B组患者在各时间点的SBP、DBP和HR均明显高于A组(P<0.05)；两组患者呼吸频率在插镜、套石、退镜各时点相比差异具有统计学意义(P<0.05),而在睁眼时则差异不明显。A组呼吸抑制、心动过缓分别为2例、12例,对照组分别为12例、2例。结论右美托咪定复合瑞芬太尼可可安全有效地应用于ERCP操作。

Clinical Observation on Dexmedetomidine and Remifentanil in the Non-pain ERCP

Objective To discuss the effectiveness and safety of dexmedetomidine and remifentanil in the ERCP. Methods 62 cases of patients planning for ERCP operation were selected and divided into two groups according to different anaes-thesia methods, the group A were given dexmedetomidine and remifentanil for anaesthesia, the group B were given propofol and remifentanil for anaesthesia, and the relevant indexes including blood pressures in each period, HR and respiratory rates of the two groups were respectively recorded. Results After the operation began, the SBP, DBP and HR in each time point in the group B were obviously higher than those in the group A, P<0.05, and there were obvious differences in the res-piratory rates between the two groups at the time of inserting endoscope, spiral stone dislodge and endoscope withdrawal, P<0.05, but the difference in the respiratory rate between the two groups at the time of eyes open was not obvious, respira-tory depression occurred to 2 cases and bradyarrhythmia occurred to 12 cases in the group A and respiratory depression oc-curred to 12 cases and bradyarrhythmia occurred to 2 cases in the control group. Conclusion Dexmedetomidine and remifentanil can effectively and safely apply to the ERCP operation.